Gencurix Inc (229000 KQ) stock market data APIs
₩1814.6542
68.59(3.8%)
as of July 9, 2025
Try our APIs with
free plan!
Gencurix Inc Financial Data Overview
Price chart is built with
Anychart
Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detection. The company has a strategic alliance with Qiagen N.V. for the development of oncology assays for use on the QIAcuityDx platform. The company was founded in 2011 and is headquartered in Seoul, South Korea.
Prev. Close
1814.6542
Open
1883.2444
High
1908.2575
Low
1824.6425
52 wk Range
1131-4150
Market Cap
28 918 M
Shares Outstanding
15 802 K
Revenue
3 394 M
EPS
-126.4559
Beta
0.495
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Gencurix Inc data using free add-ons & libraries
Get Gencurix Inc Fundamental Data
Gencurix Inc Fundamental data includes:
- Net Revenue: 3 394 M
- EBITDA: -9 408 916 480
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-09
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Gencurix Inc News
New
Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays
Qiagen N.V. (NYSE:QGEN) ranks among the best CRISPR stocks to buy. Qiagen N.V. (NYSE:QGEN) and Gencurix announced a collaboration on June 18 to provide oncology assays for Qiagen’s QIAcuityDx digita...
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
QIAGEN N.V. QGEN has announced a new partnership with South Korea-based GENCURIX, Inc. to develop oncology assays for use on the QIAcuityDx digital PCR (dPCR) platform. The molecular diagnostics compa...
Qiagen and Gencurix partner on oncology diagnostic assays
VENLO, Netherlands - QIAGEN (NYSE: QGEN), a $10 billion molecular diagnostics company with excellent financial health according to InvestingPro analysis, and GENCURIX (KOSDAQ: 229000) announced a part...
QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
GENCURIX partnership marks launch of new QIAcuityDx Partnering Program for third-party in vitro diagnostic (IVD) assay development GENCURIX signs as inaugural partner to develop multiplex oncology as...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
